(2R,4R,5R,6S)-11-methyl-5-(oxan-2-yloxy)-4-[(oxan-2-yloxy)methyl]-3,7-dioxa-1,9-diazatricyclo[6.4.0.0{2,6}]dodeca-8,11-dien-10-one | 351523-06-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (2R,4R,5R,6S)-11-methyl-5-(oxan-2-yloxy)-4-[(oxan-2-yloxy)methyl]-3,7-dioxa-1,9-diazatricyclo[6.4.0.0{2,6}]dodeca-8,11-dien-10-one
• 英文别名: (2R,3R,3aS,9aR)-7-Methyl-3-(tetrahydro-pyran-2-yloxy)-2-(tetrahydro-pyran-2-yloxymethyl)-2,3,3a,9a-tetrahydro-furo[2',3':4,5]oxazolo[3,2-a]pyrimidin-6-one；(2R,4R,5R,6S)-11-methyl-5-(oxan-2-yloxy)-4-(oxan-2-yloxymethyl)-3,7-dioxa-1,9-diazatricyclo[6.4.0.02,6]dodeca-8,11-dien-10-one
• CAS: 351523-06-3
• 化学式: C₂₀H₂₈N₂O₇
• 分子量: 408.452
• InChiKey: CXZNQOKLTCYKEH-IMBNWFMCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.67
• 重原子数：
  29.0
• 可旋转键数：
  5.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  90.27
• 氢给体数：
  0.0
• 氢受体数：
  9.0

反应信息

• 作为反应物：
  描述：

  (2R,4R,5R,6S)-11-methyl-5-(oxan-2-yloxy)-4-[(oxan-2-yloxy)methyl]-3,7-dioxa-1,9-diazatricyclo[6.4.0.0{2,6}]dodeca-8,11-dien-10-one 在 4-二甲氨基吡啶 sodium hydroxide 、 potassium carbonate 、 三乙胺 、 4,7,13,16,21,24-六氧-1,10-二氮双环[8.8.8]二十六烷 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 20.0~95.0 ℃ 、230.0 kPa 条件下， 反应 11.25h， 生成 tert-butyl [(2R,3S,4R,5R)-2-[3-(2-(18F)fluoranylethyl)-5-methyl-2,4-dioxopyrimidin-1-yl]-4-(oxan-2-yloxy)-5-(oxan-2-yloxymethyl)oxolan-3-yl] carbonate
  参考文献：
  名称：

  WO2008/109080

  摘要：

  公开号：
• 作为产物：
  描述：

  5-甲基尿甙 在 碳酸二苯酯 、 碳酸氢钠 、 对甲苯磺酸 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 (2R,4R,5R,6S)-11-methyl-5-(oxan-2-yloxy)-4-[(oxan-2-yloxy)methyl]-3,7-dioxa-1,9-diazatricyclo[6.4.0.0{2,6}]dodeca-8,11-dien-10-one
  参考文献：
  名称：

  Design, Synthesis and Enzymatic Activity of Highly Selective Human Mitochondrial Thymidine Kinase Inhibitors

  摘要：

  Highly selective arabinofuranosyl nucleosides, which inhibit the mitochondrial thymidine kinase (TK-2) without affecting the closely related herpes simplex virus type 1 thymidine kinase (HSV-1 TK), varicella-zoster virus thymidine kinase (VZV-TK), cytosolic thymidine kinase (TK-1) or the multifunctional Drosophila melanogaster deoxyribonucleoside kinase (Dm-dNK), have been obtained. SAR studies indicate a close relation between the length of the substituent at the 2' position of the arabinofuranosyl moiety and the inhibitory activity. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00207-4

文献信息

• Synthesis and evaluation of thymidine-5′-O-monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase
  作者：Veerle Vanheusden、Hélène Munier-Lehmann、Sylvie Pochet、Piet Herdewijn、Serge Van Calenbergh

  DOI：10.1016/s0960-894x(02)00551-6

  日期：2002.10

  A number of 2'- and 3'-modified thymidine 5'-O-monophosphate analogues were synthesized as potential leads for new anti-mycobacterial drugs. Evaluation of their affinity for Mycobacterium tuberculosis thymidine monophosphate kinase showed that a 2'-halogeno substituent and a 3'-azido function are the most favorable leads for further development of potent inhibitors of this enzyme. (C) 2002 Elsevier Science Ltd. All rights reserved.
• [EN] COMPOUNDS AND METHODS FOR TREATING DISEASE<br/>[FR] COMPOSÉS ET MÉTHODES POUR TRAITER UNE MALADIE
  申请人：[en]ROME THERAPEUTICS, INC.

  公开号：WO2023178133A1

  公开（公告）日：2023-09-21

  The invention provides compounds, compositions and methods for treating medical disorders, such as cancer, an autoimmune disorder, and/or a neurological disorder, and inhibiting LINE1 reverse transcriptase and/or HERV-K reverse transcriptase using a compound according to Formula I or a pharmaceutically acceptable salt thereof, or a related compound provided herein.